EDIT vs GILD · rev $32.3M vs P/E 18, rev $29.44B
Editas Medicine Inc (EDIT) versus Gilead Sciences Inc (GILD) — a side-by-side from cached financials, not a winner call.
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
Latest reported GILD revenue for 2025-12-31 was $29.44B. Net income was $8.51B. Revenue was up 2.4% from 2024-12-31 to 2025-12-31. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
EDIT currently screens at market cap $375.2M. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Not investment advice. Open the EDIT and GILD stock pages for the full models.
Not investment advice.